FP-100
- Generic Name
- FP-100
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: GSK2190915 300Drug: placeboDrug: GSK2190915 100Drug: FP/SAL 100/50
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 162
- Registration Number
- NCT01156792
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath